HER‐2/neu is overexpressed infrequently in patients with prostate carcinoma

BACKGROUND The overexpression of HER‐2/neu is found in 20–30% of patients with breast carcinoma and is an adverse prognostic factor. HER‐2 overexpression also has been reported in up to 60% of patients with hormone‐refractory prostate carcinoma (HRPC) and was correlated with shortened survival. Tras...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer 2002-05, Vol.94 (10), p.2584-2589
Hauptverfasser:	Lara, Primo N., Meyers, Frederick J., Gray, Carl R., Gandour Edwards, Regina, Gumerlock, Paul H., Kauderer, Caren, Tichauer, Garrett, Twardowski, Przemyslaw, Doroshow, James H., Gandara, David R.
Format:	Artikel
Sprache:	eng
Schlagworte:	HER‐2/neu hormone‐refractory prostate carcinoma immunohistochemistry trastuzumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!